GlobalData Healthcare

On 18 May 2025, at the American Thoracic Society International Conference, held in San Francisco, California, post hoc findings from the Phase IIa COURSE trial (NCT04039113) shed light on the potential for tezepelumab to reduce exacerbation rates in chronic obstructive […]

In April 2025, the European Medicines Agency (EMA) approved Eisai and Biogen’s Leqembi for early-stage Alzheimer’s disease, marking Europe’s first major nod for a disease-modifying Alzheimer’s therapy in over a decade. This milestone underscores Europe’s cautious regulatory approach, especially when

US President Donald Trump has issued an executive order aimed at easing regulatory challenges for domestic pharmaceutical producers while imposing stricter conditions on foreign manufacturers. The executive order, signed on 5 May 2025, instructs the US Food and Drug Administration

Chimeric antigen receptor T-cell (CAR-T) therapeutics have emerged as a dominant cancer treatment within cell and gene therapies (CGT). The CAR-T landscape is dominated by blood cancers, which account for more than half of all CAR-Ts in the active pipeline

A recent study published in Diabetologia has identified insulinoma-associated protein 2 autoantibody (IA-2A) positivity as a significant marker for disease progression in individuals at risk of type 1 diabetes (T1D). IA-2A is an autoantibody targeting the insulinoma-associated protein 2, commonly

As the field of regenerative medicine continues to advance, the incorporation of AI is playing a transformative role in the pharmaceutical industry. AI-driven drug discovery can analyse millions of chemical compounds in a fraction of the time it would take

Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the repair, regeneration, or replacement of damaged or diseased human cells and tissues. Ryoncil is an allogeneic mesenchymal stromal cell (MSC) therapy indicated for the

At the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2025, held on 13-15 February, final results from the randomised, multicentre, double-blind, Phase III COSMIC-313 clinical trial were presented. The trial evaluated the effect of triplet therapy with Exelixis’s

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft demand for gene therapies among haemophilia patients and physicians. This announcement comes after other news that Pfizer ended its partnership with Sangamo

Clinical operations teams can expect a tremendous return on investments in artificial intelligence (AI) in the next 5–10 years, according to speakers from pharmaceutical and biotech companies and investors speaking at SCOPE 2025 in Orlando, Florida, on 4-5 February 2025.